https://pralsetinibinhibitor.c....om/quit-atrial-tensi
After propensity score matching and adjusting for possible confounders there was nevertheless no difference in survival (HR 0.8, 95% CI, 0.61-1.06, P = .12). Very nearly 1 / 2 of the clients (45%) got a dose strength 75%, 50%-75%, and less then 50% were 9.5 months, 12.9 months, and 7.1 months (P = .005) respectively. In multivariable models, starting dose(HR 1.16, 95% CI 0.93-1.44, P = .18 and mean dose intensity were not associated with success. Conclusions beginning HCC pat
Like
Comment
Share
